Cencora, Inc.
About Cencora, Inc.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $321.3B
- Net income
- $1.6B
- Total assets
- $76.6B
- Market cap
- $53.5B
- Gross margin
- 3.6%
- Operating margin
- 0.8%
- Net margin
- 0.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $321.3B
- Cost of revenue
- $309.9B
- Gross profit
- $11.5B
- Operating expenses
- $7.0B
- Operating income
- $2.6B
- Income tax
- $690.5M
- Net income
- $1.6B
- EPS (basic)
- $8.02
- EPS (diluted)
- $7.96
Balance sheet
- Total assets
- $76.6B
- Current assets
- $52.2B
- Total liabilities
- $74.8B
- Current liabilities
- $57.8B
- Shareholders’ equity
- $1.7B
Cash flow
- Operating cash flow
- $3.9B
- Investing cash flow
- -$5.0B
- Financing cash flow
- $2.2B
- Net cash flow
- $1.1B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $53.5B
- P/E ratio
- 34.4
- EPS (diluted)
- $7.96
- Dividend yield
- 0.88%
- Shares outstanding
- 195.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 4, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.6B in FY2025.
- Revenue grew 56006% from FY2019 to FY2025.
- Gross margin of 3.6%, net margin 0.5%.
- Trading 27% below its 52-week high.
- Pays a dividend yielding about 0.88% annually.
- Valued at a price-to-earnings (P/E) ratio of 34.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Cencora, Inc..
Write a review
News about Cencora, Inc.
News & sentiment via Polygon.io
